Green Rush Podcast: Dr. Deborah Mash of DemeRx Inc.
Advertising Feature: This podcast is from a partner and was not produced by GreenState.
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture.
This week Anne Donohoe and Nick Opich are back for a new episode with special guest Deborah Mash, PhD, CEO & President of DemeRx Inc., a clinical stage drug development company. Dr. Mash joins us this week to discuss how ibogaine works in the brain and body, the drug’s therapeutic potential to treat addiction, the various “ah-ha” moments she’s experienced in her career and how that led her to focus on psychedelic medicines, and what’s next for the company and medicinal psychedelics.
If you are interested in learning more about DemeRX Inc. and ibogaine, visit the link in our show notes. Also, be sure to follow Dr. Mash and DemeRX Inc. on LinkedIn.
So sit back and enjoy our conversation with Dr. Mash of DemeRX Inc.
Links and mentions in the show
- Collaboration with ATAI: https://www.demerx.com/atai-life-sciences-announces-joint-venture-with-demerx-to-develop-ibogaine-for-opioid-use-disorder/
- Stanford trials of veterans using ibogaine outside of US: https://classic.clinicaltrials.gov/ct2/show/NCT04313712
Links to the guest’s company and social media accounts
- DemeRX Inc. LinkedIn: https://www.linkedin.com/company/demerx-inc.
- Deborah Mash, PhD LinkedIn: https://www.linkedin.com/in/deborah-c-mash-4680a66/
This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications.
Special thanks to our Program Director Shea Gunther.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing email@example.com. You can also connect with us via our social channels:
An Advertising Feature means this post did not originate from the newsroom but rather was inspired by the sales department. It is not a paid post, but the sales team and their clients may benefit from increased readership of this relevant content.